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Abstract
Objective: The main goal was to evaluate the effectiveness of early palliative care in patients with advanced
cancer.
Methods: The search in the MEDLINE/PubMed, CRD, Cochrane Library, CINAHL, EMBASE, Google Scholar,
ICTRP and ClinicalTrials.gov databases was conducted in June 2017. Two reviewers independently screened titles
and abstracts with consensus agreement. We undertook quality assessment according to GRADE criteria.
Randomized Controlled Trials (RCT) that assessed the effectiveness of EPC in adult patients with a diagnosis-
advanced cancer were included. The quantitative evidence was summarized in a meta-analysis using random effect
models.
Results: The selection phase retrieved 14,026 records, 7 papers were included in the meta-analysis. The
standardized mean difference the outcomes assessed were: improvement quality of life (0.17 higher; 95% CI; 0.05,
0.29) after 3 months, (0.42 higher; 95% CI; 0.21, 0.63) after 6 months, and (0.16 higher; 95% CI; -0.20, 0.53) after
12 months; improvement of symptom intensity (-0.13 lower; 95% CI; -0.26, 0.00) after 3 months, (-0.27 lower; 95%
CI; -0.53, -0.01) after 6 months, and (-0.39 lower; 95% CI; -0.76, -0.03) after 12 months; improve depressive mood
(-0.19 lower; 95% CI; - 0.36, -0.01) after 3 months, (-0.21 lower; 95% CI; -0.45, 0.04) after 6 months, and (-0.09
lower; 95% CI; -0.81, 0.63) after 12 months; and survival (OR = 0.71 higher; 95% CI; 0.51, 0.99).
Conclusion: Our findings suggest that EPC effectively improves quality of life and consequently increases the
likelihood of survival of patients with advanced or metastatic cancer. However, due to worsening of the disease
stage over time, a limited effect was observed after 12 months of follow-up.
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Introduction
Despite the advances in the treatment of cancer, the disease at an
advanced stage carries a poor prognosis. Typically, in people with
advanced cancer, social functions decline in parallel with the physical
decline over time, whereas psychological and spiritual wellbeing often
fall together into four main moments: around diagnosis, on return
home after the initial treatment, the recurrence of the disease and in
the terminal phase [1]. These issues can result in a negative impact on
the quality of life and survival of these patients [2].
The World Health Organization (WHO) has defined palliative care
as "an approach that improves the quality of life of patients and their
families facing the problem associated with life-threatening illness,
through the prevention and relief of suffering by means of early
identification and impeccable assessment and treatment of pain and
other problems, physical, psychosocial and spiritual” [3].
This does not mean that palliative care should only be considered
when all therapeutic options have failed or when a person is
considered to be at the end of their life. According to clinical
guidelines, palliative care can be offered after diagnosis and combined
with standard oncology care [4,5]. Therefore, the objective this
systematic review was to determine the effectiveness of Early Palliative
Care (EPC) in terms of improving Quality of Life (QoL) and survival
in patients with advanced cancer, as compared to standard care.
Methods
A systematic review was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidance (S1 Table) [6]. The protocol has been registered with the
International Prospective Register of Systematic Reviews (PROSPERO)
(CRD42017065309).
Eligibility criteria
We included all Randomized Controlled Trials (RCTs) that met the
following inclusion criteria:
• Population composed of adult patients diagnosed with advanced
cancer
• Patients in the intervention arm received EPC
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• Patients in the comparator arm received standard care
• Outcomes evaluated included measurements of QoL and survival.
Search
A literature search was undertaken using multiple electronic
databases: MEDLINE (via PubMed), Centre for Reviews and
Dissemination (CRD), The Cochrane Library, Cumulative Index to
Nursing and Allied Health Literature (CINAHL), EMBASE, and
Google Scholar. Additionally, International Clinical Trial Registry
Platform and ClinicalTrials.com website were also searched for
ongoing studies.
The search strategy combined search terms for palliative care,
neoplasm, quality of life, and survival. Further, specific search filters
for RCTs were also applied. All searches were performed from
inception to June 2017. The strategies used in the searched electronic
databases are presented in Appendix 1.
Study selection
Search results from the different databases were imported and
merged into Cochrane’s tool – Covidence and duplicates were removed
automatically or deleted manually. Two reviewers (FZ and IZ)
independently assessed the titles and abstracts retrieved to identify
potential papers for inclusion. Following which, both reviewers
reviewed the remaining full papers. All disagreement was resolved
through discussions until consensus was reached. If consensus cannot
be met between the two reviewers, the opinion of a third reviewer
(CASA) was sought.
Data extraction
Finally with the articles deemed relevant selected, the information
on the characteristics of these studies (design, methods of
randomization, population, interventions, and results) was extracted
using the standardized data collection form. When such information
could not be retrieved, an email was sent to authors requesting non-
reported data.
Risk of bias
Risk of bias of individual studies was assessed using the Cochrane
Risk of Bias (RoB 2.0) tool. This tool considers five domains and each
domain was classified as having "low risk" (+), "high risk" (-) or unclear
risk (?) of bias.
Risk of bias across studies was assessed using the Grading of
Recommendations Assessment, Developing, and Evaluation (GRADE)
approach [7,8]. It was intended that potential publication and small
study bias across the studies would also be investigated through funnel
plots. However, due to the small number of studies identified for the
review, this was not carried out [9].
Statistical analysis
The outcomes estimates were pooled in a meta-analysis, using
random-effects models based on the DerSimonian-Laird method. The
random effects model accounts for sampling error and between study
variations. This model is preferable when there is heterogeneity in
outcomes and provide estimates that are more conservators [10]. In
addition, fixed effect models were also used as the sensitivity analysis.
The predictive interval that incorporates the extent of heterogeneity
and inconsistency in the analysis, was used to assess the extent of
uncertainty in the size of the estimated effect in each measured
outcome [11].
Considering that the selected studies used different instruments to
measure the outcomes, it is not meaningful to combine the effect size
by raw mean differences. In this case usually, the estimated effect size is
measured employing the Hedges'g or Cohen's d statistic [12,13].
The two statistics are very similar, however, the Cohen’s tending to
overestimate the absolute value in small samples. Meta-analyses
performed employed a conservative approach using the Hedges'g
statistic. We divided the mean difference between the two groups by
pooled and weighted Standard Deviation (SD) of the groups to create a
Standardized Mean Difference (SMD) that would be comparable
across studies [12]. When not reported, missing SD was imputed using
the sample size weighted SD from all of the studies with complete
information.
The outcomes measured as SMD have the objective of comparing
the results across different studies through of different measures. For
this reason, it cannot be interpreted as a difference in rating scale
points or percent improvement. One approach for interpreting the
magnitude of the SMD is to use the widely accepted guidelines of
Cohen [13].
For SMDs, he defined 0.2 as a small effect, 0.5 as a medium effect,
and 0.8 as large. Odds Ratio (OR) for survival was calculated using the
randomized effect model.
Statistical heterogeneity was assessed and quantified using the
Cochran’s Q and I2. Due to the small number of studies included in the
meta-analysis, we used p<0.10 as an indication of statistical
significance and evidence of heterogeneity [14,15]. All analyses were
carried out using Stata 14 [16].
Results
Study selection
Figure 1 describes a flow diagram of the process of identifying
relevant studies to be included in the review. Overall, the databases
search retrieved 14,026 articles, of which 81 were read in full. Further
exclusions yielded eight studies which met all the inclusion criteria
(Table 1). Reasons for exclusion of studies are listed in the S2 Table.
Citation: Zanghelini F, Zimmermann IR, Andrade CAS, Wu O (2018) Early Palliative Care for Improving Quality of Life and Survival in Patients
with Advanced Cancer: A Systematic Review and Meta-analysis. J Palliat Care Med 8: 343. doi:10.4172/2165-7386.1000343
Page 2 of 9
J Palliat Care Med, an open access journal
ISSN:2165-7386
Volume 8 • Issue 5 • 1000343
Figure 1: Flow diagram of prospection of studies comparing the effectiveness of EPC versus standard care.
Characteristics
Bakitas et al.
2009 [18]
Temel el al.
2010 [19]
Tattersall et al.
2014 [20]
Zimmermann et
al. 2014 [21]
Bakitas et al.
2015 [22]
McCorkle et al.
2015 [23]
Maltoni et al.
2016 [24]
Temel et al.
2016 [25]
EPC Std.care EPC
Std.
care EPC
Std.
care EPC
Std.
care EPC
Std.
care EPC
Std.
care EPC
Std.
care EPC
Std.
care
N 145 134 77 74 53 54 228 233 104 103 66 80 97 89 175 175
Mean age (SD) 65.4(10)
65.2
(11)
64.9
(9)
64.8
(9)
63
(11) 64 (11)
61.2
(12)
60.2
(11)
64.0
(10)
64.6
(9) 60 60 67 66
65.6
(11)
64.0
(10)
Male (%) 90(62)
78
(58)
35
(45)
38
(51)
32
(53) 26 (43) 92 (40)
108
(46)
56
(55)
53
(52) 19 (29) 45 (56)
59
(62)
47
(53)
91
(52)
98
(56)
Female (%) 55(38)
56
(42)
42
(55)
36
(49)
28
(47) 34 (57)
136
(60)
125
(54)
48
(46)
50
(48) 47 (71) 35 (44)
37
(38)
42
(47)
84
(48)
77
(44)
White (%) 143(99)
132
(99)
77
(100)
70
(95) - - - -
102
(98)
98
(95) 58 (88) 66 (83) - -
156
(89)
167
(95)
American (%) - - - - - - - - - - - - - - 4 (2) 0 (0)
Asian (%) - - 0 1 (1) - - - - - - - - - - 5 (3) 3 (2)
Black (%) - - 0 3 (4) - - - - 0 1 (1) - - - - 6 (3) 4 (2)
Hispanic (%) - - - - - - - -   - - - - 7 (4.0) 2 (1.1)
Other (%) 1 (0.7) 1 (0.7) - - - - - - 2 (2) 3 (3) 8 (12) 14 (17) - - 4 (2) 1 (0.6)
Missing (%) 1 (0.7) 1 (0.7) - - - - - - 0 1 (1) - - - - - -
Lung (%) 50(34)
43
(32)
77
(51)
74
(49)
12
(20) 11 (18) 55 (24) 46 (20)
46
(44)
42
(41) 37 (56) - - -
95
(54)
96
(55)
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Gastrointestinal
(%)
61
(42)
58
(43) - -
20
(33) 24 (40) 74 (32) 65 (28)
26
(25)
24
(23) - 53 (66)
97
(52)
89
(48)
80
(46)
79
(45)
Genitourinary (%) 19(13)
18
(13) - - - - 27 (12) 51 (22) 7 (7) 9 (9) - - - - - -
Breast (%) 15(10)
15
(11) - - 5 (8) 12 (20) 41 (18) 31 (13)
10
(10)
13
(13) - - - - - -
Gynaecological
(%) - - - -
11
(18) 8 (13) 31 (14) 40 (17) - - 29 (44) - - - - -
Other solid tumour
(%) - - - -
12
(20) 3 (5) - -
10
(10)
10
(10) - - - - - -
Hematologic
malignancy (%) - - - - - - - - 5 (5) 5 (6) - - - - - -
Prostate (%) - - - - 0 (0) 2 (3) - - - - - - - - - -
Head and neck
(%) - - - - - - - - - - - 27 (34) - - - -
Never smoker or <
10 pack-years (%) - -
18
(24)
16
(22) - - - -
72
(70)
73
(71) - - - -
75
(43)
67
(38)
Current or former
smoker (%) - - - - - - - -
17
(24)
14
(20) - - - -
93
(53)
95
(54)
Unknown (%) - - - - - - - - - - - - - - 7 (4) 13 (7)
High School or
Less (%)
17
(12)
20
(15) - - - - 18 (8) 24 (10) 8 (8) 3 (3) 18 (27) 24 (30) - -
58
(33)
73
(42)
Some or Complete
college (%)
83
(57)
74
(55) - -
23
(38) 32 (53) 56 (25) 57 (24)
61
(59)
50
(49) 48 (73) 56 (70) - -
76
(43)
69
(40)
Graduate School
(%)
43
(30)
38
(28) - - - -
152
(65)
151
(65)
35
(34)
50
(49) - - - -
41
(23)
33
(19)
Chemotherapy (%) 107(74)
96
(72)
50
(65)
46
(65) - -
174
(76)
182
(78)
76
(73)
80
(78) 28 (42) 36 (45) - - - -
Radiation therapy
(%)
30
(21)
30
(22)
27
(35)
26
(35) - - 16 (7) 13 (6)
20
(19)
20
(19) - - - - - -
NOTE: EPC = Early Palliative Care, N = number of patients, Std. Care = Standard care
Table 1: Characteristics of included studies.
Study characteristics
Of the eight studies included, three were undertaken in the USA,
two in the Lebanon, and one each in Canada, Australia, and Italy
[17-24]. Across the studies selected, the number of patients assessed in
each study ranged from 107-461, with the mean age of the patients
ranging from 60 to 67 years old. The most evaluated cancer types were
lung, gastrointestinal, genitourinary, breast and gynecological cancer.
Intervention class
We include all types of professional EPC services provided to
patients in advanced stages of cancer. In addition, patients needed to
be enrolled in palliative care soon after diagnosis of advanced disease.
We did not include palliative therapies to prolong life (e.g. palliative
chemotherapy) or relieve symptoms (e.g. palliative radiotherapy). We
did not restrict the type of delivery of EPC (inpatient, outpatient) or
place of consultation (clinic, patient’s home).
Beyond standard cancer treatment, the EPC included monitoring
patients’ status, symptom management, problem-solving,
communication and social support, and advance care planning.
Patients met with nurse and palliative care physicians to routine
assessment and discussion of goals of care, or patient and family
support needs. The clinical practices were guided by specific guidelines
for people and families living with cancer. Two main ways of delivering
the EPC were identified across of selected RCTs:
• intervention carried out mainly by telephone and face to face
(called and face to face) [17,19-22] and
• patients have met with a member of the palliative care team (face-
to-face) [18,23,24].
Patients assigned to standard care group were allowed to use all
standard cancer treatments.
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Outcome assessment
Quality of life was measured using the Functional Assessment of
Chronic Illness Therapy (FACIT) tool [25–27]. This tool have a score
range of 0 to 184 and measures the physical, emotional, social, and
functional well-being of people with life-threatening illnesses. Higher
scores indicate better QoL. Symptoms intensity was measured by
Edmonton Symptom Assessment Scale (ESAS) and Symptom Distress
Scale (SDS) [28,29]. Scoring ranges from 0 to 900 and 13 to 65,
respectively. Both tools assess the intensity of the most common
symptoms in cancer, such as pain, activity, nausea, depression, anxiety,
drowsiness, appetite, feeling of well-being, and shortness of breath.
Higher scores indicate a greater intensity of symptoms. The mood was
measured by the instruments, Patient Health Questionnaire-9
(PHQ-9), Center for Epidemiological Studies Depression Scale (CES-
D), and Hospital Anxiety and Depression Scale (HADS) [30-32]. Their
scores range from 0 to 27, 0 to 60, and 0 to 21, respectively. In both
instruments, higher scores indicate a greater level of depressed mood.
The survival rate was assessed through a log-rank test to compare
Kaplan-Meier survival curves between the two groups. Mean and SD
values were requested when provided only the mean observed change
from baseline [20]. The studies varied in relation to follow-up and
assessment time: 3, 6, and 12 months.
Risk of bias
According to Cochrane risk of bias tool, the methods used for
allocation concealment and measurement of the outcomes were not
clearly stated and show some concerns. Conversely, the methods for
deviations from intended interventions, missing outcomes data, and
selection of the reported results were appropriately described in all
studies. Overall, the risk of bias in the studies showed some concerns
(S3 Table).
Considering that the study by Tattersall et al. showed a failure in
randomization and high risk of bias due the patients assigned to the
EPC group had an initial diagnosis of cancer of more than 3 months
and with a worse survival estimate, this study was not considered in
the meta-analysis [19].
Synthesis of results
We identified heterogeneity in relation to the type of intervention
provided to patients in the EPC group, we observed also differences in
follow-up time, time of enrollment in the study after the initial
diagnosis, and in estimates of survival (prognosis) (S4 Table). In this
case, a sensitivity analysis was performed, separating the studies
according to the follow-up time to evaluate the effect of the
intervention over time.
Quality of Life – QoL
Pooled data showed that patients enrolled in EPC presented a
significantly higher QoL than those attributed to standard care (SMD
0.17, 95% CI 0.05, 0.29 at 3 months and, SMD 0.42, 95% CI 0.21, 0.63
after 6 months). According to Cohen's criteria, the magnitude of the
outcome assessed was small [13]. A qualitatively similar result was
obtained by the fixed effect model. Considering the level of
heterogeneity and statistical uncertainty observed, the estimated effect
of a new study would be between (-0.05, 0.39) and (-1.34, 2.17) after 3
and 6 months, respectively.
After 12 months of follow-up, the evidence shows that there is no
statistically significant difference between the two groups assessed
(SMD 0.16, 95% CI -0.20, 0.53). Based on Cochran’s Q and Higgin’s I2,
there is no statistic evidence of heterogeneity between the studies
(Figure 2).
Figure 2: Forest plot comparing EPC vs. standard care in terms of improvement of QoL.
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Using approach GRADE, we downgrade the quality of the evidence
to moderate because the studies presented some concerns regarding
the bias arising from the randomization process and the outcome
assessor was aware of the intervention received [18,20–22] (S5 Table).
Additionally, McCorkle assessed in the intervention group, older
patients with more chronic conditions, and diagnosed with later-stage
cancers [22].
Symptom intensity
Data pooled showed that the symptom intensity was significantly
lower in EPC group after 3, 6, and 12 months follow-up (SMD -0.13,
95% CI -0.26, -0.00; SMD -0.27, 95% CI -0.53, -0.01; and SMD -0.39,
95% CI -0.76, -0.03) (Figure 3). The effect size was small and no
heterogeneity across studies was found. A qualitatively similar result
was obtained through of fixed effect analysis.
Figure 3: Forest plot comparing EPC vs. standard care in terms of improvement of symptom intensity.
Mood
The analysis showed that the depressed mood level did not differ
between the evaluated groups. Given the level of heterogeneity and
statistical uncertainty observed, the effect of a new study would be
between (-0.65, 0.27) and (-2.60, 2.19) after 3 and 6 months,
respectively (Figure 4).
Based on Cochran’s Q and Higgin’s I2, the outcome is characterized
by qualitative heterogeneity between the studies. Some factors that
influenced the inconsistency and imprecision are shown in S3 and S4
Table. Using approach GRADE, we downgrade the overall quality of
evidence in the following criteria: risk of bias [19,21-23], inconsistency
[20–22], and imprecision [17,20-24] (S5 Table).
Survival
The outcome showed that the OR below 1.0, represent a lower odds
of mortality in the EPC group. The median survival time ranged from
11.6 to 18 months for the EPC group and 8.5 and 11.8 months for the
standard care group. Available evidence indicates that patients
undergoing the EPC have 29% lower chance of mortality than patients
undergoing standard care, with the true effect in the population
between 49% and 1% lower: OR=0.71, 95% CI 0.51, 0.99, P=0.04). This
outcome was based on a set of studies homogeneous from the statistic
viewpoint: PQ=0.63 with I2=0% (Figure 5). Using approach GRADE,
the confidence of evidence was rated as moderate. Making a practical
interpretation of the effect size, the EPC reduces 85 deaths per 1,000
patients (95% CI 2 to 166).
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Figure 4: Forest plot comparing EPC vs. standard care in terms of decrease of depressed mood level.
Figure 5: Forest plot for survival analysis comparing EPC vs. standard care.
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Discussion
Main results
Considering a decrease in health over time, we combined the
evidence on the effectiveness of EPC in patients with advanced cancer
in subgroups according to the time of follow-up. On average, the
Quality of Life in the early palliative care group was higher after 3 and
6 months of follow-up. Additionally, patients enrolled in EPC group
presented lower symptoms intensity and longer survival. A similar
benefit was observed between EPC services provided through
telehealth and face-to-face.
According to Murray et al. , a fall in the trajectory of psychological
and spiritual wellbeing can occur at four moments during the
evolution of disease: around diagnosis, on return home, at recurrence,
and in the terminal phase [1]. The limited effect on the improvement of
QoL and depressed mood observed after 12 months of follow-up can
be explained by the variation in the trajectory of wellbeing and disease
progression.
Overall, the quality of evidence and the strength of the
recommendation showed some concerns and had been classified
between very low and moderate. Second Zimmermann, the evidence
on the effectiveness of palliative care is scarce and with methodological
limitations, such as contamination of the control group, substantial
failure in recruitment, attrition, and adherence [33].
The result of our meta-analysis contributes to the increasing
evidence that early palliative care may improve quality of life and
survival of patients with advanced or metastatic cancer, which are two
of the main target of care [3,34].
Completeness, applicability, and overall quality of evidence
Although we have made a highly sensitive electronic search, the
result of our systematic review identified few studies published in the
literature. We believe that the best evidence available was found,
however, the pooled data from seven studies maintains the
uncertainties surrounding the effect of EPC. According to search made
in the International Clinical Trial Registry Platform and
ClinicalTrials.gov website, new RCTs are ongoing and can contribute to
raising the strength of evidence.
Some studies showed differences related to the patients assigned to
the EPC group and this may have affected the quality and
heterogeneity of the evidence [20,22,24]. Others concerns that deserve
to be addressed are: comparing the effect of providing early versus
delayed palliative care and the trade-off of recruit highly distressed
patients due to newly diagnosed advanced cancer may limit the ability
to identify the differences and affect outcomes [21,22].
Potential biases in the review process
A potential bias that we can highlight is the non-recovery of studies
carried out but not published. At this stage, it is difficult to say such
studies actually exist. We consider this number to be too small or non-
existent. Moreover, it is reasonable to assume that such studies would
probably not qualitatively change the overall outcome obtained.
Although traditional meta-analysis methods are robust to an
inadequate assumption of normality, the confidence intervals of the
summarized estimates should be seen as reasonable approximations of
the true population parameter [35].
Implications for clinical practice and health services
The provision of palliative care aims to alleviate suffering and
achieve the quality of life of patients and their family caregivers.
Results found shown that EPC is appropriate and potentially beneficial
when introduced after diagnosis and combined with standard
oncology care. Some questions still need to be clarified. For example,
the reason for greater survival in the EPC group is unknown. This
benefit may be due to improved QoL or improved symptom severity.
However, the studies assessed were not designed to assess this
question.
Implication for research
New studies with robust, stratified samples by cancer type are
needed to assess the effectiveness and to identify the best ways to
provide EPC. Additionally, studies that assess the effect of EPC on
overall health care costs need to be performed.
Conclusion
Our findings suggest that EPC effectively improves QoL, reduces
symptoms, and increases the likelihood of survival of patients with
advanced cancer. Although the effect size has been small, clinically it
may be relevant considering a decrease in health over time. Finally, the
results should be interpreted with caution due there are few published
studies and the quality of evidence observed.
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